Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma Following Autologous Stem Cell Transplant.
A. Keith Stewart , Christine Chen , Kang Howson-Jan , Darrell White
Blood 104 ( 11) 335 -335
9
2004
Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.
M J O'Connell , C Erlichman , M J Kahn , L E Shepherd
Journal of Clinical Oncology 14 ( 10) 2887
5
1996
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
M N Levine , V H Bramwell , K I Pritchard , B D Norris
Journal of Clinical Oncology 16 ( 8) 2651 -2658
728
1998
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
K I Pritchard , A H Paterson , S Fine , N A Paul
Journal of Clinical Oncology 15 ( 6) 2302 -2311
90
1997
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
J M S Bartlett , , T O Nielsen , D Gao
British Journal of Cancer 113 ( 5) 722 -728
4
2015
Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial
M. J. Burnell , E. M. O'Connor , J. W. Chapman , M. N. Levine
Journal of Clinical Oncology 26 ( 15_suppl) 550 -550
9
2008
Use of elevated bone turnover to predict bone metastasis
A. Lipton , J. W. Chapman , L. Demers , L. E. Shepherd
Journal of Clinical Oncology 26 591 -591
4
2008
NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer
M. N. Pollak , J. W. Chapman , K. I. Pritchard , J. E. Krook
Journal of Clinical Oncology 26 ( 15_suppl) 532 -532
13
2008
Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF
M. Cheang , S. K. Chia , D. Tu , S. Jiang
Journal of Clinical Oncology 27 ( 15_suppl) 519 -519
41
2009
Characterization of 25-OH vitamin D (Vit D) and factors associated with obesity in patients with high-risk breast cancer (BC): NCIC CTG MA.21.
E. V. Tsvetkova , J. W. Chapman , T. D. Baetz , M. J. Burnell
Journal of Clinical Oncology 28 1578 -1578
1
2010
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
F. P. O’Malley , S. Chia , D. Tu , L. E. Shepherd
Breast Cancer Research and Treatment 128 ( 2) 401 -409
36
2011
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
S. F. Dent , J. Botros , M. Rushton , O. Aseyev
Breast Cancer Research and Treatment 184 ( 3) 733 -741
2020
Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience
L. E. Shepherd , W. Parulekar , K. I. Pritchard , M. Trudeau
Journal of Clinical Oncology 24 522 -522
11
2006
Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)
F. P. O’Malley , S. Chia , D. Tu , L. E. Shepherd
Journal of Clinical Oncology 24 533 -533
31
2006
NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women
B. Moy , D. Tu , L. E. Shepherd , J. L. Pater
Journal of Clinical Oncology 24 6018 -6018
1
2006
Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial.
V. Stearns , J. W. Chapman , C. X. Ma , M. J. Ellis
Journal of Clinical Oncology 29 525 -525
9
2011
Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study.
D. L. Hershman , A. M. Cheung , J. W. Chapman , J. N. Ingle
Journal of Clinical Oncology 29 518 -518
8
2011
Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer.
R. Yerushalmi , B. Dong , J. W. Chapman , P. E. Goss
Journal of Clinical Oncology 29 513 -513
1
2011
The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.
M. C. U. Cheang , D. Voduc , D. Tu , S. Jiang
Journal of Clinical Oncology 29 1032 -1032
3
2011
Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort.
D. Sgroi , E. Carney , E. Richardson , L. Steffel
Journal of Clinical Oncology 29 2 -2
1
2011